

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Elapegademase
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EZN-2279 in Patients With ADA-SCID
Details : EZN-2279 is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Severe Combined Immunodeficiency.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 19, 2011
Lead Product(s) : Elapegademase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
